Diagnostic performance of [¹²⁴I]m-iodobenzylguanidine PET/CT in patients with pheochromocytoma

Ziel/Aim ^123/131I-MIBG scintigraphy has shown a high specificity for imaging pheochromocytoma and paraganglioma however with low sensitivity due to low spatial resolution. ¹²⁴I-MIBG PET may overcome this limitation to improve the staging of patients with (suspected) pheochromocytoma.

Methodik/Methods We analyzed the sensitivity, specificity, positive and negative predictive values (PPV, NPV) of ¹²⁴I-MIBG PET in 43 consecutive patients with suspected (recurrence of) pheochromocytoma using histopathological (n=25) and clinical validation (n=18) as standard of truth. Furthermore, we compared ¹²⁴I-MIBG PET versus contrast enhanced CT (CE-CT) per-patient and per-lesion detection rate of ¹²⁴I-MIBG PET in 13 additional patients with known metastatic malignant pheochromocytoma (MMP).

Ergebnisse/Results ¹²⁴I-MIBG PET/CT was positive in 19/43 (44%) patients with suspected pheochromocytoma. Presence of pheochromocytoma was confirmed in 22/43 (51%). ¹²⁴I-MIBG PET/CT sensitivity, specificity, PPV, NPV were 86%, 100%, 100%, 88%, respectively. ¹²⁴I-MIBG PET was positive in 11/13 (85%) MMP patients. Combined ¹²⁴I-MIBG PET and CE-CT detected 173 lesions, of which 166 (96%) and 118 (68%) were visible on ¹²⁴I-MIBG PET and CE-CT, respectively.

Schlussfolgerungen/Conclusions ¹²⁴I-MIBG PET detects pheochromocytoma with high accuracy at initial staging and high detection rate at re-staging. Future assessment of ¹²⁴I-MIBG PET for treatment guidance including personalized ¹³¹I-MIBG therapy is warranted.

 

Scroll to top

Publication History

Article published online:
14 April 2022